The Neurotalk-2022 Scientific Committee is inviting the submission of scientific abstracts for proffered paper and
poster sessions.
Authors are asked to submit abstracts under one of the following categories, but not limited:
Cellular and Molecular Neuroscience |
Behavioral and Cognitive Neuroscience |
Neurophysiology |
Computational and Theoretical Neuroscience |
Alzheimer's Disease and Dementia |
Cerebrovascular Disease and Stroke |
Epilepsy and Seizure Disorders |
Parkinson's Disease |
Neuromuscular Disease |
Drug Addiction |
Brain Cancer |
Traumatic Brain Injury |
Schizophrenia |
Autism |
Neurorehabilitation |
Neurosurgery |
Neuro Imaging |
Neural Interface Technology |
Neuroengineering |
Neuropharmacology |
Neuropathic Pain |
Neural Stem Cell Therapy |
Pain Management Nursing |
Headache and Migraine |
Emerging Antiaging Technologies |
Geriatric Oncology and Cancers |
Geriatric Palliative Medicine and End of Life Care |
Geriatric Nursing |
Psychological Sciences and Elderly Health |
Obesity, Diabetes and Cerebrovascular Diseases |
Abstracts must be in English and contain a maximum of 2800 characters with space in Microsoft Word. A data
table may be included where required, but will count as 600 characters against the 2800 characters total. A
maximum of 1 image file may also be included, but each image will count as 600 characters against the 2800
characters total. All abstracts accepted by the Scientific Committee will be published in the conference
proceeding. The Scientific Committee will review all submitted abstracts, and will determine if an abstract is
to be presented orally, by poster, or by publication only.
Abstracts failing to meet minimum standards or are not relevant to this conference will be declined. Authors
may submit multiple abstracts, but usually an individual will not be offered more than one oral presentation.
Add: Life Science Innovation Center BLD 3-2, 43 Torch Road, High Tech Park, Dalian, LN 116023, China
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2010-2022 BIT Congress Inc.